CN112313213A - 3-氨基吡唑类化合物及其应用 - Google Patents

3-氨基吡唑类化合物及其应用 Download PDF

Info

Publication number
CN112313213A
CN112313213A CN201980022751.4A CN201980022751A CN112313213A CN 112313213 A CN112313213 A CN 112313213A CN 201980022751 A CN201980022751 A CN 201980022751A CN 112313213 A CN112313213 A CN 112313213A
Authority
CN
China
Prior art keywords
amino
oxy
pyrazole
methyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980022751.4A
Other languages
English (en)
Other versions
CN112313213B (zh
Inventor
丁克
耿美玉
陈成斌
丁健
谈理
艾菁
张章
彭霞
任小梅
季寅淳
段云鑫
戴阳
涂正超
陆小云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Jinan University
Shanghai Haihe Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Jinan University
Shanghai Haihe Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Jinan University, Shanghai Haihe Pharmaceutical Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN112313213A publication Critical patent/CN112313213A/zh
Application granted granted Critical
Publication of CN112313213B publication Critical patent/CN112313213B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

本发明涉及式(Ⅰ)所示结构的3‑氨基吡唑类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子或者其氘代物及其应用。该化合物及其药物组合物可作为蛋白激酶抑制剂，有效抑制AXL蛋白激酶的活性并且能抑制多种肿瘤细胞的增殖、迁移和侵袭。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201980022751.4A 2018-03-27 2019-03-26 3-氨基吡唑类化合物及其应用 Active CN112313213B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018102607591 2018-03-27
CN201810260759 2018-03-27
PCT/CN2019/079733 WO2019184918A1 (zh) 2018-03-27 2019-03-26 3-氨基吡唑类化合物及其应用

Publications (2)

Publication Number Publication Date
CN112313213A true CN112313213A (zh) 2021-02-02
CN112313213B CN112313213B (zh) 2023-01-31

Family

ID=68062527

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980022751.4A Active CN112313213B (zh) 2018-03-27 2019-03-26 3-氨基吡唑类化合物及其应用

Country Status (2)

Country Link
CN (1) CN112313213B (zh)
WO (1) WO2019184918A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499583B (zh) * 2020-05-22 2022-02-15 沈阳工业大学 喹唑啉衍生物及其作为抗肿瘤药物的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079294A1 (en) * 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
CN101321751A (zh) * 2005-09-30 2008-12-10 布里斯托尔-迈尔斯·斯奎布公司 Met激酶抑制剂
US20110130393A1 (en) * 2008-07-31 2011-06-02 Michael Altman Inhibitors of janus kinases
CN106467541A (zh) * 2015-08-18 2017-03-01 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN107667101A (zh) * 2015-04-14 2018-02-06 奎利恩特有限公司 作为tam rtk抑制剂的喹啉衍生物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101321751A (zh) * 2005-09-30 2008-12-10 布里斯托尔-迈尔斯·斯奎布公司 Met激酶抑制剂
WO2008079294A1 (en) * 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
US20110130393A1 (en) * 2008-07-31 2011-06-02 Michael Altman Inhibitors of janus kinases
CN107667101A (zh) * 2015-04-14 2018-02-06 奎利恩特有限公司 作为tam rtk抑制剂的喹啉衍生物
CN106467541A (zh) * 2015-08-18 2017-03-01 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JULIO CABALLERO ET AL.: ""Docking and quantitative structure–activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine ……"", 《J COMPUT AIDED MOL DES》 *

Also Published As

Publication number Publication date
WO2019184918A1 (zh) 2019-10-03
CN112313213B (zh) 2023-01-31

Similar Documents

Publication Publication Date Title
EP3339294B1 (en) Quinolone derivative, pharmaceutical acceptable salt, or stereoisomer thereof as axl inhibiotor
ES2816382T3 (es) Compuestos de alquinilbenceno heterocíclicos, y composiciones médicas y usos de los mismos
JP6474068B2 (ja) ２−アミノピリミジン系化合物およびその薬物組成物と使用
CN103012399B (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
CN108530444B (zh) 一种新型nampt和ido双重抑制剂及其制备方法和医药用途
WO2022253283A1 (zh) 一类蛋白激酶降解剂及其用途
CN112351971B (zh) 喹啉或喹唑啉类化合物及其应用
CN112313213B (zh) 3-氨基吡唑类化合物及其应用
CN114539263B (zh) 一类含氮并杂环化合物及其药用组合物和应用
CN112851667B (zh) 含氮并杂环类化合物及其药用组合物和应用
WO2021180008A1 (zh) 含脲结构的三芳环化合物及其应用
CN103570731A (zh) 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
EA042574B1 (ru) Соединение на основе хинолина или хиназолина и его применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210202

Assignee: Shanghai Haihe pharmaceutical research and Development Co.,Ltd.

Assignor: Jinan University|SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES|Shanghai Haihe pharmaceutical research and Development Co.,Ltd.

Contract record no.: X2021980000575

Denomination of invention: 3-aminopyrazole compounds and their applications

License type: Exclusive License

Record date: 20210122

GR01 Patent grant
GR01 Patent grant